Opioids

Member Information (required)	Provide	Provider Information (required)	
Member Name:	Provider Name:	Specialty:	
ID#:	NPI#:	Contact Person	
Date of Birth:	Office Phone:	Office Fax:	
Pha	rmacy Information		
Pharmacy Name:	Pharmacy NPI:		
Pharmacy Phone:	Pharmacy Fax:		
Medicat	ion Information (requir	red)	
Medication Name:	Strength:	Dosage Form:	
Directions for use:			
Effective January 1, 2019 Utah Medicaid will adopt equivalent dose (MED) methodology for adjudication daily MED thresholds will be established; a thresholor an opioid in the last 90 days, and 180 MED for the last 90 days from the index opioid prescription.	on of all opioid claims for the toold of 90 MED for "opioid naïve opioid experienced" individuated The MED threshold for opioid	reatment of non-cancer pain. Two sets of e" individuals who have not had a claim als who have had a claim for an opioid in dexperienced individuals will be reduced	
FDA Black Box Warning: Concomitant use of opic depressants, including alcohol, may result in profoct concomitant prescribing for use in patients for who durations to the minimum required; and follow patients. Note: Providers will need to complete sections, as cong Acting Opioids: Patient must have received therapy on a long acting opioid. Criteria for Approval: 1) Member is < 18 years old? □Yes □No 2) Documented clinical rationale why the member buprenorphine, and naloxone or naltrexone me	pids with benzodiazepines or und sedation, respiratory deprim alternative treatment option ents for signs and symptoms of applicable. If a prescription for a short actor has a paid claim for any buptons.	other central nervous system (CNS) ression, coma, and death. Reserve as are inadequate; limit dosages and of respiratory depression and sedation. ting opioid within 30 days of initiating renorphine-naloxone combination,	
The Black Box Warning: Concomitant use of opic depressants, including alcohol, may result in profoct concomitant prescribing for use in patients for who durations to the minimum required; and follow patients. Note: Providers will need to complete sections, as cong Acting Opioids: Patient must have received therapy on a long acting opioid. Criteria for Approval: Member is < 18 years old? □Yes □No Documented clinical rationale why the member buprenorphine, and naloxone or naltrexone measurements. Combinations with Long Acting Opioids: Patients along acting opioid. Criteria for Approval: Please indicate the patient's diagnosis for taking a long acting opioid. Criteria for Approval: Please indicate the patient's diagnosis for taking adjunct for relief of skeletal muscle spasms □ panic disorder □ sleep □ other: □ Step Document the fill date of the patient's last opioid Document the fill date for the patient's last bent being treated for a sleep disorder □ sleep □ other: □ Step Dose Opioids Criteria for approval: Is the member currently using or has tried and opioid analgesics, antidepressants, or anticonverse.	pids with benzodiazepines or and sedation, respiratory deprim alternative treatment option ents for signs and symptoms of applicable. If a prescription for a short act of a prescription for a short act of a prescription within the past 18 months are a paid claim of any buping a benzodiazepine: anxiety converted converted	other central nervous system (CNS) ression, coma, and death. Reserve res are inadequate; limit dosages and of respiratory depression and sedation. ting opioid within 30 days of initiating renorphine-naloxone combination, onths for a benzodiazepine within 45 days of vulsive disorders	

UTAH DEPARTMENT OF HEALTH, PRIOR AUTHORIZATION REQUEST FORM

2)	If the MME limit is exceeded, provide clinical rationale and supporting chart notes:
3)	Provide plan to taper, if available.
Pro	ovider Attests to all of the following:
1)	Provider has a signed opioid treatment agreement with the member? □Yes □No
2)	Provider has checked the Utah's Controlled Substance Database with each prescription? □Yes □No
3)	Provider has discussed with the member benefits and potential harm, including combining opioids with other CNS
	depressants? □Yes □No
4)	Provider has counseled members with high-risk conditions (sleep apnea, pregnancy, mental health conditions,
_\	substance abuse disorders, or children) are aware of the heightened risk of using opioids? □Yes □No
5)	Member has received naloxone education? □Yes □No
	tial authorization: One (1) month -authorization: Up to three (3) months
	ertify that the benefits of opioid treatment for this patient outweigh the risks and verify that the information provided on s form is true and accurate to the best of my knowledge.
 Pre	escriber's Signature Date